LEADER 01071nam0-22003851i-450 001 990001648770403321 005 20201103092033.0 010 $a88-206-2467-2 035 $a000164877 035 $aFED01000164877 035 $a(Aleph)000164877FED01 035 $a000164877 100 $a20030910d1984----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $aa 001yy 200 1 $aPiante tossiche o dannose agli animali$fPier Luigi Verona 210 $aBologna$cEdagricole$d1984 215 $aVII, 125 p.$cill.$d24 cm 610 0 $aPiante tossiche 610 0 $aPiante tossiche o dannose agli animali 676 $a581.69 676 $a581.65$v23$zita 700 1$aVerona,$bPier Luigi$0353712 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990001648770403321 952 $aVI5 C 16$b11849$fDMVSF 952 $a60 581.65 VERP 1984$b52$fFAGBC 952 $a615.1-5$b8276$fDMVBF 959 $aFAGBC 959 $aDMVSF 959 $aDMVBF 996 $aPiante tossiche o dannose agli animali$9371787 997 $aUNINA LEADER 05789nam 22006855 450 001 9910978383703321 005 20250207115241.0 010 $a9789819770229 010 $a981977022X 024 7 $a10.1007/978-981-97-7022-9 035 $a(MiAaPQ)EBC31900195 035 $a(Au-PeEL)EBL31900195 035 $a(CKB)37498916500041 035 $a(OCoLC)1499719824 035 $a(DE-He213)978-981-97-7022-9 035 $a(EXLCZ)9937498916500041 100 $a20250207d2024 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNanotechnology Based Strategies for Cancer Immunotherapy $eConcepts, Design, and Clinical Applications /$fedited by Rajeev Sharma, Vikas Pandey, Neeraj Mishra 205 $a1st ed. 2024. 210 1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2024. 215 $a1 online resource (636 pages) 311 08$a9789819770212 311 08$a9819770211 327 $aIntroduction to cancer immunotherapy -- Therapeutic hallmark of cancer & immunology -- Novel immunotherapeutic approaches for cancer therapy -- Recent advances in bio material for Immunotherapeutic applications -- Combination therapies for the management of cancer immunotherapy -- Cancer Vaccines as Immunotherapeutic frontier -- Dendritic Cell based approaches in cancer immunotherapy -- Peptides based Vaccines in cancer immunotherapy -- Monoclonal antibodies based nanobiotechnology based approaches in cancer immunotherapy -- Chimeric Antigen Receptor T Cells Based Cancer Immunotherapy -- Polymer and lipid based nanocomplexes in cancer immunotherapy -- Role of the tumor microenvironment in cancer immunotherapy -- Inorganic nanoparticles based strategies for Cancer Immunotherapy -- POLYMERIC NANOPARTICLES BASED STRATEGIES FOR CANCER IMMUNOTHERAPY -- Advances in Lipid-based nanosystem for immune induction in cancer immunotherapy -- Design, implementation and interpretation of clinical trials of cancer immunotherapy -- Ethical considerations of cancer immunotherapy, and patient perspectives on the benefits and risks of treatment -- REGULATORY ASPECTS OF CANCER IMMUNOTHERAPY -- Clinical applications, Patents and challenges in cancer immunotherapy. 330 $aThis book will give an up-to-date and thorough exposition of the state of the art of concepts, design, and recent advances in nanobiotechnology-based strategies for cancer Immunotherapy, and their current and clinical status. Nanobiotechnology-based Targeted therapies and Immunotherapy have been added to the effective oncologic treatment and have become increasingly popular in oncology. It is intended to enable the researchers to prepare a variety of Nanobiotechnology-based strategies, investigate their properties, and discover their uses and applications in cancer immunotherapy. The novelty of the approach is to address an existing need to understand exhaustively the potential of the nanotechnology-based approaches, including targeted and smartly designed therapies, that deliver loaded immunoreactive (s) into the body at predefined sites. The book will also discuss the patents related to cancer immunotherapy. Because of the versatility and wide range of properties, nanobiotechnology-based systems are extensively used in cancer immunotherapy. The task of obtaining a versatile candidate in immune component(s) delivery seems to be intricated, as it has to surpass several vigorous clinical barriers. As a result, many scientists rely on nanobiotechnology-based approaches, which have already been approved and well-established. Over the years, extensive research has been undertaken on the delivery of immunoreactive(s) using nanotechnology-based delivery systems. With advancements in nanobiotechnology, more needs are realized to develop nanoengineered/smart delivery systems with even more convoluted properties. Currently, research is mainly focused on nanoengineered systems, which can perform one or more of the desired functions. The proposed book summarizes the basic principles and research supporting cancer immunotherapy clinical translation contains nanobiotechnology-based treatment strategies for all immunotherapy classes and agents, including cell-based therapies, monoclonal antibodies, cytokine therapies, checkpoint inhibitors, oncolytic viruses, adjuvant approaches, treatment combinations Includes information on all FDA-approved immunotherapies, for individual cancer types, including melanoma and other skin cancers, lung cancers, gastrointestinal cancers, hematologic cancers, genitourinary cancers, head and neck cancers, sarcomas, brain cancers, and breast cancer etc. Also explains the regulatory aspects behind the development and approval of immunotherapy drugs. 606 $aCancer 606 $aNanomedicine 606 $aCancer$xTreatment 606 $aImmunotherapy 606 $aTumors$xImmunological aspects 606 $aCancer Nanotechnology 606 $aCancer Therapy 606 $aImmunotherapy 606 $aTumour Immunology 615 0$aCancer. 615 0$aNanomedicine. 615 0$aCancer$xTreatment. 615 0$aImmunotherapy. 615 0$aTumors$xImmunological aspects. 615 14$aCancer Nanotechnology. 615 24$aCancer Therapy. 615 24$aImmunotherapy. 615 24$aTumour Immunology. 676 $a616.994 676 $a620.5 700 $aSharma$b Rajeev$0275577 701 $aPandey$b Vikas$01786764 701 $aMishra$b Neeraj$01770631 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910978383703321 996 $aNanotechnology Based Strategies for Cancer Immunotherapy$94318935 997 $aUNINA